AIMS/HYPOTHESIS: The aim of this study was to examine the association between baseline body iron stores and new-onset diabetes. SUBJECTS AND METHODS: We studied the association between baseline serum ferritin concentration and type 2 diabetes in 360 clinically incident diabetes cases and 758 controls nested within the EPIC (European Prospective Investigation of Cancer)-Norfolk Cohort Study. Serum ferritin levels were categorised into five groups: sex-specific quartiles of the normal range of ferritin and a group with clinically raised ferritin below levels indicative of haemochromatosis. RESULTS: Baseline serum ferritin was higher among cases than control participants (geometric mean: men 96.6 vs 67.8 ng/ml, respectively, p < 0.001; women 45.9 vs 34.8 ng/ml, respectively, p = 0.005). In analyses adjusted for known risk factors (age, BMI, sex, family history, physical activity, smoking habit) and dietary factors measured by 7-day food diary, the risk of diabetes was markedly elevated in participants with clinically raised ferritin compared with the lowest quartile (odds ratio [OR] 7.4, 95% CI 3.5-15.4). Further adjustment for potential confounding by inflammation (C-reactive protein, IL-6 and fibrinogen) had no material impact on the observed association, while adjustment for hepatic enzymes (alanine aminotransferase and gamma glutamyl transferase) and adiponectin attenuated the magnitude of association, but it remained statistically significant (OR 3.2 [1.3-7.6]). CONCLUSIONS/ INTERPRETATION: Serum ferritin is an important and independent predictor of the development of diabetes. This finding may have important implications for understanding the aetiology of diabetes.
AIMS/HYPOTHESIS: The aim of this study was to examine the association between baseline body iron stores and new-onset diabetes. SUBJECTS AND METHODS: We studied the association between baseline serum ferritin concentration and type 2 diabetes in 360 clinically incident diabetes cases and 758 controls nested within the EPIC (European Prospective Investigation of Cancer)-Norfolk Cohort Study. Serum ferritin levels were categorised into five groups: sex-specific quartiles of the normal range of ferritin and a group with clinically raised ferritin below levels indicative of haemochromatosis. RESULTS: Baseline serum ferritin was higher among cases than control participants (geometric mean: men 96.6 vs 67.8 ng/ml, respectively, p < 0.001; women 45.9 vs 34.8 ng/ml, respectively, p = 0.005). In analyses adjusted for known risk factors (age, BMI, sex, family history, physical activity, smoking habit) and dietary factors measured by 7-day food diary, the risk of diabetes was markedly elevated in participants with clinically raised ferritin compared with the lowest quartile (odds ratio [OR] 7.4, 95% CI 3.5-15.4). Further adjustment for potential confounding by inflammation (C-reactive protein, IL-6 and fibrinogen) had no material impact on the observed association, while adjustment for hepatic enzymes (alanine aminotransferase and gamma glutamyl transferase) and adiponectin attenuated the magnitude of association, but it remained statistically significant (OR 3.2 [1.3-7.6]). CONCLUSIONS/ INTERPRETATION: Serum ferritin is an important and independent predictor of the development of diabetes. This finding may have important implications for understanding the aetiology of diabetes.
Authors: A A Welch; A McTaggart; A A Mulligan; R Luben; N Walker; K T Khaw; N E Day; S A Bingham Journal: Public Health Nutr Date: 2001-12 Impact factor: 4.022
Authors: Bruce B Duncan; Maria Inês Schmidt; James S Pankow; Heejung Bang; David Couper; Christie M Ballantyne; Ron C Hoogeveen; Gerardo Heiss Journal: Diabetes Date: 2004-09 Impact factor: 9.461
Authors: Robert C Cooksey; Deborah Jones; Scott Gabrielsen; Jingyu Huang; Judith A Simcox; Bai Luo; Yudi Soesanto; Hugh Rienhoff; E Dale Abel; Donald A McClain Journal: Am J Physiol Endocrinol Metab Date: 2010-03-30 Impact factor: 4.310
Authors: Amalia Gastaldelli; Lucia Perego; Michele Paganelli; Giorgio Sesti; Marta Hribal; Alberto O Chavez; Ralph A Defronzo; Antonio Pontiroli; Franco Folli Journal: Obes Surg Date: 2008-09-24 Impact factor: 4.129
Authors: Veikko Salomaa; Aki Havulinna; Olli Saarela; Tanja Zeller; Pekka Jousilahti; Antti Jula; Thomas Muenzel; Arpo Aromaa; Alun Evans; Kari Kuulasmaa; Stefan Blankenberg Journal: PLoS One Date: 2010-04-09 Impact factor: 3.240
Authors: Ivonne Sluijs; Joline W J Beulens; Daphne L van der A; Annemieke M W Spijkerman; Diederick E Grobbee; Yvonne T van der Schouw Journal: Diabetes Care Date: 2009-10-13 Impact factor: 19.112